Biotech By Megan Molteni UC Berkeley loses CRISPR patent case, invalidating patent rights it granted gene-editing companies developing human therapies
Biotech By Adam Feuerstein Intellia Therapeutics shows improved, sustained effect from in vivo CRISPR treatment
Biotech By Megan Molteni With new trial data coming, Intellia CEO talks up the future of in vivo gene editing
The Readout LOUD By Damian Garde and Meg Tirrell Jennifer Doudna and Marty Chavez on where CRISPR meets Wall Street
The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Robert Califf’s FDA return, the future of CRISPR, & another vaccine delay
In the Lab By Megan Molteni Drugs based on next-generation gene editing are moving toward the clinic faster than CRISPR 1.0
Biotech By Megan Molteni In the wake of big patent decision, it’s business as usual for CRISPR therapy developers
Exclusive By Megan Molteni New details emerge about a U.S. scientist’s obscured role in the ‘CRISPR babies’ scandal
The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein Listen: Biden’s plans for Covid pills, the latest vaccine data, & fighting about CRISPR
Biotech By Matthew Herper and Megan Molteni Bayer to pay CRISPR-focused Mammoth Biosciences $40 million for gene editing research
In the Lab By Megan Molteni New CRISPR tools could fix diseases caused by large DNA rearrangements, scientists report
Biotech By Adam Feuerstein Editas CRISPR treatment improved vision for one patient, but not others, early data show
Biotech By Matthew Herper and Megan Molteni Return of the mammoth? George Church-backed company launches with $15 million for elephant-sized quest
In the Lab By Megan Molteni A new technology, based on a quirk of evolutionary biology, may be the next big thing for CRISPR
STAT Summit By Megan Molteni Extending the reach of gene therapies means hurdling not just scientific barriers but prices, too
The Readout LOUD By Meg Tirrell, Adam Feuerstein and Damian Garde Regeneron’s George Yancopoulos talks CRISPR, obesity drugs, and the next generation of Covid antibody cocktails
The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein Listen: A CRISPR milestone, Biogen’s FDA saga, & George Yancopoulos on biotech in 2021
Biotech By Megan Molteni In a first for genome editing, Intellia Therapeutics reports positive early data on in vivo CRISPR therapy
Biotech By Adam Feuerstein CRISPR Therapeutics, Nkarta to jointly develop engineered natural killer cells as cancer treatments
Biotech By Megan Molteni Beam Therapeutics unveils new CRISPR base editing tool to target the sickle cell mutation
First Opinion By Patrick Skerrett Q&A with ‘Code Breaker’ author Walter Isaacson on CRISPR, patents, and more
The Readout LOUD By Damian Garde, Meg Tirrell and Adam Feuerstein Listen: J&J’s imminent vaccine data, CRISPR’s confusing boom, and navigating scientific misinformation
Biotech By Adam Feuerstein Preliminary but ‘nothing short of great.’ New data on CRISPR treatment for blood diseases suggest cure is possible
Biotech By Adam Feuerstein CRISPR Therapeutics’ CAR-T treatment shows encouraging results, but one death is tied to therapy
First Opinion By Patrick Skerrett The CRISPR Nobel was about more than two women scientists. It was about all of them